JP2019512207A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512207A5
JP2019512207A5 JP2018536458A JP2018536458A JP2019512207A5 JP 2019512207 A5 JP2019512207 A5 JP 2019512207A5 JP 2018536458 A JP2018536458 A JP 2018536458A JP 2018536458 A JP2018536458 A JP 2018536458A JP 2019512207 A5 JP2019512207 A5 JP 2019512207A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
variable region
chain variable
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018536458A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512207A (ja
JP7022067B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/013511 external-priority patent/WO2017124001A2/en
Publication of JP2019512207A publication Critical patent/JP2019512207A/ja
Publication of JP2019512207A5 publication Critical patent/JP2019512207A5/ja
Application granted granted Critical
Publication of JP7022067B2 publication Critical patent/JP7022067B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018536458A 2016-01-14 2017-01-13 Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体 Expired - Fee Related JP7022067B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662278815P 2016-01-14 2016-01-14
US62/278,815 2016-01-14
PCT/US2017/013511 WO2017124001A2 (en) 2016-01-14 2017-01-13 T cell receptor-like antibodies specific for foxp3-derived peptides

Publications (3)

Publication Number Publication Date
JP2019512207A JP2019512207A (ja) 2019-05-16
JP2019512207A5 true JP2019512207A5 (enExample) 2020-02-20
JP7022067B2 JP7022067B2 (ja) 2022-02-17

Family

ID=59311684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536458A Expired - Fee Related JP7022067B2 (ja) 2016-01-14 2017-01-13 Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体

Country Status (5)

Country Link
US (1) US11505599B2 (enExample)
EP (1) EP3402518A4 (enExample)
JP (1) JP7022067B2 (enExample)
CN (1) CN109069627A (enExample)
WO (1) WO2017124001A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016281641B2 (en) * 2015-06-23 2022-01-20 Eureka Therapeutics, Inc. Novel PD-1 immune modulating agents
IL295398B2 (en) 2015-10-23 2025-01-01 Eureka Therapeutics Inc Antibody/T-cell receptor chimeric constructs and their uses
CN110741016A (zh) 2017-04-26 2020-01-31 优瑞科生物技术公司 嵌合抗体/t-细胞受体构筑体及其用途
US20210147550A1 (en) * 2017-08-18 2021-05-20 Joshua Michael Francis Antigen-binding proteins targeting shared antigens
EP3752601A4 (en) * 2018-02-15 2022-03-23 Memorial Sloan-Kettering Cancer Center FOXP3-TARGETING AGENT COMPOSITIONS AND METHODS OF USE FOR ADOPTIVE CELL THERAPY
US12325757B2 (en) * 2018-12-21 2025-06-10 Zhejiang Shimai Pharmaceutical Co., Ltd. Protease cleavable bispecific antibodies and uses thereof
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
WO2022221669A1 (en) * 2021-04-15 2022-10-20 Kyverna Therapeutics, Inc. Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agents
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
AU2024217436A1 (en) * 2023-02-06 2025-08-14 Eureka Therapeutics, Inc. Compositions including anti-wt-1 antibodies antigen binding fragments and uses thereof
WO2025145063A1 (en) * 2023-12-29 2025-07-03 Eureka Therapeutics, Inc. Constructs targeting msln peptide/mhc complexes and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1975A (en) 1841-02-12 Manner of constructing corn-shellers
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
PT1391464E (pt) * 2001-04-27 2007-11-15 Kirin Pharma Kk Anticorpo monoclonal anti-cd40
US9320792B2 (en) * 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
JP2006519763A (ja) 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． 治療用ポリペプチドの投与法およびそのためのポリペプチド
US20100003253A1 (en) 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
ES2426725T3 (es) 2004-05-27 2013-10-24 Crucell Holland B.V. Método para identificar moléculas de unión que pueden neutralizar el virus de la rabia
JP4829609B2 (ja) 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
US8361462B2 (en) * 2005-09-01 2013-01-29 National Research Council Of Canada Anti-apoptotic protein antibodies
EP2064350B1 (en) 2006-11-27 2013-01-02 Ludwig Institute for Cancer Research Ltd. Expression of foxp3 by cancer cells
TWI441648B (zh) 2007-01-03 2014-06-21 Oncotherapy Science Inc Ｆｏｘｐ３胜肽疫苗
WO2009003489A1 (en) * 2007-07-02 2009-01-08 Natimmune A/S CaOU-1 EPITOPE BINDING POLYPEPTIDES
EP2020419A1 (en) 2007-07-31 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Anti ephB4 antibody fragments
US20110038935A1 (en) * 2007-12-06 2011-02-17 Marasco Wayne A Antibodies against influenza virus and methods of use thereof
JP5432727B2 (ja) * 2008-01-29 2014-03-05 株式会社抗体研究所 Ａ型ボツリヌス毒素中和組成物及びヒト抗ａ型ボツリヌス毒素抗体
WO2009134339A2 (en) * 2008-04-29 2009-11-05 Monsanto Technology, Llc Genes and uses for plant enhancement
US20120005773A1 (en) * 2008-10-01 2012-01-05 Aasen Eric D Transgenic plants with enhanced agronomic traits
CA2742968C (en) * 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
US20120117685A1 (en) * 2009-02-27 2012-05-10 Wei Wu Isolated Novel Nucleic Acid and Protein Molecules from Soybeans and Methods of Using Thos Molecules
US9180186B2 (en) 2010-01-11 2015-11-10 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9540433B2 (en) 2011-02-01 2017-01-10 Genmab A/S Human antibodies and antibody-drug conjugates against CD74
WO2015070061A1 (en) 2013-11-07 2015-05-14 Memorial Sloan-Kettering Cancer Center Anti-wt1/hla bi-specific antibody
US20130102031A1 (en) 2011-10-25 2013-04-25 Anaptysbio, Inc. Use of somatic hypermutation to create insertion and deletion mutations in vitro
KR102410078B1 (ko) * 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
US9561266B2 (en) * 2012-08-31 2017-02-07 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
MY182431A (en) * 2013-12-24 2021-01-25 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
GB201410520D0 (en) 2014-06-12 2014-07-30 Univ London Queen Mary Antibody

Similar Documents

Publication Publication Date Title
JP2019512207A5 (enExample)
CN107405397B (zh) 抗tim-3抗体
JP2020501531A5 (enExample)
CN110891650A (zh) 制导和导航控制蛋白及其制造和使用方法
KR20180114218A (ko) 항-lag-3 항체
CN108337890A (zh) 新型pd-1免疫调节剂
JP2019524693A5 (enExample)
JP2021511818A (ja) Ｖｉｓｔａ抗原結合性分子
JP2017535257A5 (enExample)
CN116948035A (zh) 多特异性抗体及其制备和使用方法
CN107428832A (zh) 抗pd‑l1抗体
JP2013506428A5 (enExample)
JP2017510251A (ja) 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体
JP2018500014A5 (enExample)
CN117946278A (zh) 多特异性抗体及其制备和使用方法
CN111655286A (zh) 作为免疫调节剂的cd96结合剂
CN112292399A (zh) 抗cd27抗体及其用途
JP7418326B2 (ja) 二重特異性抗体並びにその製造方法及び使用方法
WO2021121373A1 (zh) 抗人程序死亡因子-1单克隆抗体
KR20210027254A (ko) Tim-3에 대한 항체 및 그의 용도
JP2016529213A5 (enExample)
Sandeep et al. Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics
AU2018370120A1 (en) Methods for selective expansion of d3 yd T-cell populations and compositions thereof
JP2020533002A5 (enExample)
TW202328196A (zh) 使用vista抗原結合分子的癌症之治療及預防